This Article Full Text (PDF) All Versions of this Article: 0885066608321246v1 23/5/313    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Begelman, S. M. Articles by Bartholomew, J. R. Search for Related Content PubMed PubMed Citation Articles by Begelman, S. M. Articles by Bartholomew, J. R. Social Bookmarking                         What's this?

Argatroban Anticoagulation in Intensive Care Patients: Effects of Heart Failure and Multiple Organ System Failure

Cleveland Clinic, Cleveland, Ohio, begelman.susan{at}gene.com

Sarkis B. Baghdasarian, MD

Cleveland Clinic, Cleveland, Ohio

Inder M. Singh, MD

Cleveland Clinic, Cleveland, Ohio

Michael A. Militello, PharmD

Cleveland Clinic, Cleveland, Ohio

Marcie J. Hursting, PhD

Clinical Science Consulting, Austin, Texas

John R. Bartholomew, MD

Cleveland Clinic, Cleveland, Ohio

We retrospectively evaluated argatroban dosing patterns, clinical outcomes, and the effects of heart failure and multiple organ system failure on dosing requirements in 65 adult, intensive care patients administered argatroban anticoagulation for clinically suspected heparin-induced thrombocytopenia (n = 56) or history of heparin-induced thrombocytopenia (n = 9). Argatroban was initiated then titrated to achieve target activated partial thromboplastin times 1.5 to 3 times normal control (ie, 42-84 seconds). Overall, argatroban was initiated at 1.14 ± 0.62 µg/kg/min (mean ± SD) and administered for 11.4 ± 9.5 days, with comparable dosing patterns between patients with suspected, versus previous, heparin-induced thrombocytopenia. Sixty-four (98.5%) patients achieved target activated partial thromboplastin times, typically following no or one dose adjustment. Therapeutic doses were lower in patients with, versus without, heart failure (0.58 ± 0.28 vs 0.97 ± 0.6 µg/kg/min, P = .042) and decreased as the number of failed organ systems increased from 1 to 2 to =3 (1.10 ± 0.67 vs 0.87 ± 0.47 vs 0.58 ± 0.47 µg/kg/min, P = .008). From argatroban initiation until patient discharge or death, 11 (16.9%) patients (3 off argatroban) developed thromboembolic complications; 14 (21.5%) died (11 off argatroban, 7 from multiple organ system failure); and 1 (1.5%) required amputation. Nine patients (13.8%) experienced bleeding, none fatal. This experience suggests that argatroban administered at approximately 1 µg/kg/min provides adequate levels of anticoagulation in many intensive care unit patients with suspected or previous heparin-induced thrombocytopenia. Reduced doses are needed when heart failure or multiple organ system failure is present.

Key Words: heparin-induced thrombocytopenia • argatroban • heart failure • multiple organ system failure

This version was published on September 1, 2008

Journal of Intensive Care Medicine, Vol. 23, No. 5, 313-320 (2008)
DOI: 10.1177/0885066608321246


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?